The marketing analysis of proton pump inhibitors market: focus on omeprazole and ezomeprazol
DOI:
https://doi.org/10.24959/sphhcj.20.201Keywords:
marketing analysis, proton pomp inhibitors, esomeprazole, omeprazole, minimal costAbstract
Aim. To perform the marketing analysis of the omeprazole and esomeprazole market assessing their “minimal cost” (cost-minimization analysis).
Materials and methods. The marketing analysis of the pharmaceutical market of omeprazole and esomeprazole was performed. An average cost of a standard pack, tablet / capsule and DDD of 36 representatives of PPI drugs (20 representatives of omeprazole and 16 ones of esomeprazole) were analyzed. Materials for the analysis were data of the “Pharm Explorer” analytical system provided by “Proxima Research Ukraine”.
Results. The study of the consumption structure indicates the dominance of proton pump inhibitors (PPI) in the sector of drug support for acid-related diseases. In 2019-2020, twenty oral forms of omeprazole and 16 forms of esomeprazole were available in Ukraine. Among all PPIs, the highest growth rate in 1Q 2020 was shown by esomeprazole (56 %) compared to the same period in 2019. The pharmacoeconomic analysis indicates that Omeprazole, JSC Farmak (Ukraine) and Omeprazole, corporation Arterium (Ukraine) are the most reasonable in terms of “minimum cost” (cost-minimization analysis). Their cost is 1.9 times lower than the cost of the drug Omez, by Dr. Reddy`s (India). When analyzing the esomeprazole market (40 mg tablets, No. 14) it was found that esomeprazole Ezoneksa, JSC Farmak (Ukraine) and Pemozar, SUN (India) with 3.8 times lower cost than the original drug Nexium by Astra Zeneca (UK) were economically reasonable for the military personnel drug support.
Conclusions. The study indicates that esomeprazole shows the highest growth rate (GR) in 1Q 2020 – by 56 % compared to the same period of 2019, and to Esonexa – by 259 %. The pharmacoeconomic analysis of the “minimum cost” (cost-minimization analysis) indicates that the drug Ezonexa by Farmak JSC (Ukraine) is economically reasonable for the military personnel drug support among the drugs of esomeprazole, while Omeprazole, Farmak JSC (Ukraine) and Omeprazole, the Arterium corporation, are the best among the omeprazoles (Ukraine).References
Bezdetko, N. V. (2011). Lіky Ukrainy, 7, 71–75. URL: http://www.health-medix.com/articles/liki_ukr/2011-08-29/11NVBGRB.pdf.
Iakovlieva, L. V. (2009). Farmakoekonomika. Vinnytsia: Nova knyha, 208.
Hughes, D. A., Bodger, K., Bytzer, P., de Herdt, D., Dubois, D. (2005). Economic analysis of on-demand maintenance therapy with proton pump inhibitors in patients with non-erosive reflux disease. Pharmacoeconomics, 23 (10), 1031-41. doi: 10.2165/00019053-200523100-00006.
Os`odlo, G. V., Honcharov, Ya. P., Besaha, V. V. (2015). Viiskova medytsyna Ukrainy, 1, 41-44.
Qi, Q., Wang, R., Liu, L., Zhao, F., Wang, S. (2015). Comparative effectiveness and tolerability of esomeprazole and omeprazole in gastro-esophageal reflux disease: A systematic review and meta-analysis. Eur. J. Clin. Pharmacol, 53 (10), 803-810. doi: 10.5414/CP202396.
Teng, M., Khoo, A. L., Zhao, Y. J., Lin, L., Lim, B. P., Wu, T. S., Dan, Y. Y. (2015). Meta-analysis of the effectiveness of esomeprazole in gastroesophageal reflux disease and Helicobacter pylori infection. J Clin Pharm Ther, 40 (4), 368-375. doi: 10.1111/jcpt.12277.
Kirchheiner, J. (2009). Relative potency of proton pump inhibitors comparison of effects on intragastric pH. Eur. J. Clin. Pharmacol, 65 (1), 19–31.
Shmatenko, O. P., Bilous, M. V., Halan, O. V., Voronenko, D. V. Drozdov, D. V. (2019). Viiskovo-farmatsevtychna lohistyka. Кyiv: Lesya, 150.
Farm Eksplorer kompanii “Proksyma Research” Ukraina. Available at: https://proximaresearch.ua/ua/.
Downloads
Published
Issue
Section
License
Copyright (c) 2020 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
